How BARDA Locked Up COVID-19 Vaccine Manufacturing Capacity For Operation Warp Speed
US agency avoided procurement delays with sole-source awards to two medical countermeasures venture partners worth nearly $900m.
You may also be interested in...
As CEO Erck touts that its COVID vaccine has the 'best data,' Novavax prepares to enter Phase III trials and inks deal with Serum Institute to boost production even as its 'almost a perfect flu vaccine' remains on hold.
Order sets a path for federal government to use its power as a purchaser of pharmaceuticals to nurture a high-tech domestic pharma manufacturing sector that would increase resilience against threats that could isolate the US from countries like China that are important nodes in the global manufacturing supply chain.
The Trump administration’s move to strengthen domestic manufacture of essential medicines raises a lot of questions – and industry’s ire.